HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis

Journal of the American College of Cardiology

Volumn 32, Issue 7, 1998, Pages 2057-2064

  Bustos, Carmen ^a   Hernández Presa, Miguel A ^a   Ortego, Mónica ^a   Tuñón, José ^a   Ortega, Luis ^b   Pérez, Fernando ^c   Díaz, Cristina ^d   Hernández, Gonzalo ^d   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Parke Davis SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANGIOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; DOWN REGULATION; ENZYME INHIBITION; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID ANALYSIS; MACROPHAGE; MALE; MORPHOMETRICS; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CHEMOKINE CCL2; CORONARY ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; EVALUATION STUDIES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; NF-KAPPA B; PYRROLES; RABBITS; RANDOM ALLOCATION; TUNICA INTIMA;

EID: 0032406276     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00487-2     Document Type: Article

References (25)

1. Brown B.G., Fuster V. Impact of management in stabilization of coronary disease. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1996;191-205 Lippincott-Raven, Philadelphia.
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
3. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
4. Van der Wal A.C., Becker A.E., Van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
5. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., Fallon J.T. Macrophage infiltration in acute coronary syndromes implication for plaque rupture . Circulation. 90:1994;775-778.
6. Ylä-Herttuala S., Lipton B.A., Rosenfeld M.E., et al. Expression of monocyte chemoattractant protein 1 in macrophage rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci. USA. 88:1991;5252-5256.
7. Ueda A., Okuda K., Ohno S., et al. NF-κB and SP1 regulate transcription of the human monocyte chemoattractant protein 1 gene. J Immunol. 153:1994;2052-2063.
8. Hernandez-Presa M., Bustos C., Ortego M., et al. Angiotensin converting enzyme inhibition prevents arterial NF-κB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1997;1532-1541.
9. Le Veen R.F., Wolf G.L., Villanueva T.G. New rabbit atherosclerosis model for the investigation of transluminal angioplasty. Invest Radiol. 17:1982;470-475.
10. Wang X.B., Watanabe Y., Osugi T., Ikemoto M., Hirata M., Miki N. In situ DNA-protein binding a novel method for detecting DNA-binding activity of transcription factor in brain . Neurosci Lett. 146:1992;25-28.
11. Chomczynski P., Sacchi N. Single-step of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
12. Liao F., Andalibi A., deBeer F.C., Fogelman A.M., Lusis A.J. Genetic control of inflammatory gene induction and NF-κB-like transcription factor activation in response to atherogenic diet in mice. J Clin Invest. 91:1993;2572-2579.
13. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
14. Fernandez-Ortiz A., Badimon J.J., Falk E., et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components Implications for consequences of plaque rupture . J Am Coll Cardiol. 23:1994;1562-1569.
15. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix-metalloproteinases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503.
16. Neiken N.A., Coughlin S.R., Gordon D., Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 88:1991;1121-1127.
17. Barnes P.J., Karin M. Nuclear factor κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1997;1066-1071.
18. Miano J.M., Vlasic N., Tota R.R., Stemerman M.B. Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol. 142:1993;715-724.
19. Chen L., Haugth W.H., Yang B., Saldeen T.G.P., Parathasarathy S., Mehta J.L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanism of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 30:1997;569-575.
20. Liao F., Andalibi A., Qiao J.H., Allayee H., Fogelman A.M., Lusis A.J. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 94:1994;877-884.
21. Guijarro C., Egido J. Modulation of the mevalonate pathway potential mechanisms of vascular protection by HMG-CoA reductase inhibitors independent of cholesterol reduction . Cardiovascular Risk Factors. 7:1997;29-35.
22. Soma M.R., Doneti E., Parolini C., et al. HMG-CoA reductase inhibitors In vivo effects of carotid intimal thickening in normocholesterolemic rabbits . Arterioscler Thromb. 13:1993;571-578.
23. Jovinge S., Hultgardh-Nilsson A., Regnström J., Nilsson J. Tumor necrosis factor-α activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Throm Vasc Biol. 17:1997;490-497.
24. Watts G.F., Lewis B., Brunt J.N.H., et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus colestiramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
25. Buchwald H., Matts J.P., Ritch L.L., et al. Effect of partial ileal bypass on mortality and morbidity on coronary artery disease in patients with hypercholesterolemia. Report of the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 323:1990;946-955.